文献速递帕金森病与运动障碍

18F-flortaucipir tau PET可区分进行性核上性麻痹与对照及帕金森病

18 F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study.
PubMed 文献 · Ann Neurol · 2017-01-01

多中心研究比较符合临床研究标准的进行性核上性麻痹(PSP)患者(n=33)、正常对照(n=46)和帕金森病(PD)患者(n=26)的18F-flortaucipir摄取。PSP患者在苍白球、壳核、丘脑底核、中脑和齿状核出现双侧摄取增高,苍白球结合最能区分PSP与对照(AUC=0.872)及PD(AUC=0.893),但摄取与临床严重程度不相关。

要点

  • PSP患者18F-flortaucipir在苍白球、壳核、丘脑底核、中脑和齿状核摄取增高。
  • 苍白球结合区分PSP与对照的AUC=0.872,与PD的AUC=0.893。
  • PSP临床严重程度与18F-flortaucipir摄取无相关性。

核心结论

  • 18F-flortaucipir在PSP患者中的摄取高于对照和PD患者,分布模式与预期tau病理分布一致。

研究设计与样本

  • 多中心研究,纳入符合临床研究标准的PSP患者33例、正常对照46例和符合标准的PD患者26例。
  • 参与者接受MRI及淀粉样蛋白(11C-PiB或18F-florbetapir)和tau(18F-flortaucipir)PET。
  • 18F-flortaucipir标准化摄取值比基于t=80-100分钟、小脑灰质参考区计算。

主要发现

  • PSP患者相对对照和PD患者在苍白球、壳核、丘脑底核、中脑和齿状核出现双侧18F-flortaucipir摄取增高(体素wise p<0.05,家族wise误差校正)。
  • 苍白球结合区分PSP与对照的AUC=0.872,区分PSP与PD的AUC=0.893。
  • PSP临床严重程度与任何脑区的18F-flortaucipir摄取均不相关。
  • 1例临床诊断PSP、病理诊断皮质基底节变性的患者,PSP相关脑结构严重tau病理,生前18F-flortaucipir与死后tau神经病理对应良好。

临床怎么用

  • 18F-flortaucipir PET可用于辅助区分PSP与帕金森病及正常对照,尤其关注苍白球摄取。

局限性

  • 仅1例患者进行了死后病理对照。
  • PSP临床严重程度与18F-flortaucipir摄取无相关性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: 18 F-flortaucipir (formerly 18 F-AV1451 or 18 F-T807) binds to neurofibrillary tangles in Alzheimer disease, but tissue studies assessing binding to tau aggregates in progressive supranuclear palsy (PSP) have yielded mixed results. We compared in vivo 18 F-flortaucipir uptake in patients meeting clinical research criteria for PSP (n = 33) to normal controls (n = 46) and patients meeting criteria for Parkinson disease (PD; n = 26). METHODS: Participants underwent magnetic resonance imaging and positron emission tomography for amyloid-β (11 C-PiB or 18 F-florbetapir) and tau (18 F-flortaucipir). 18 F-flortaucipir standardized uptake value ratios were calculated (t = 80-100 minutes, cerebellum gray matter reference). Voxelwise and region-of-interest group comparisons were performed in template space, with receiver operating characteristic curve analyses to assess single-subject discrimination. Qualitative comparisons with postmortem tau are reported in 1 patient who died 9 months after 18 F-flortaucipir. RESULTS: Clinical PSP patients showed bilaterally elevated 18 F-flortaucipir uptake in globus pallidus, putamen, subthalamic nucleus, midbrain, and dentate nucleus relative to controls and PD patients (voxelwise p < 0.05 family wise error corrected). Globus pallidus binding best distinguished PSP patients from controls and PD (area under the curve [AUC] = 0.872 vs controls, AUC = 0.893 vs PD). PSP clinical severity did not correlate with 18 F-flortaucipir in any region. A patient with clinical PSP and pathological diagnosis of corticobasal degeneration had severe tau pathology in PSP-related brain structures with good correspondence between in vivo 18 F-flortaucipir and postmortem tau neuropathology. INTERPRETATION: 18 F-flortaucipir uptake was elevated in PSP versus controls and PD patients in a pattern consistent with the expected distribution of tau pathology. Ann Neurol 2017;82:622-634.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Schonhaut DR, McMillan CT, Spina S, et al. 18 F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study. Ann Neurol. 2017. PMID: 28980714. doi:10.1002/ana.25060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。